image 2 image 4
Skip Navigation Links
 Home 
 Congress Structure 
 Important Dates 
 Venue 
 Registration 
 Pre Registered 
 Hotel Info 
 Abstracts 
 Scientific Program 
 Social Program 
 Exhibition 
 Contact Us 
       XXIV Annual Congress of the Iranian Society of Ophthalmology        بـیــست و چهارمین کنــگــره سـالیـانه انـجـمـن چـشـم پـزشـکی ایـــران
مقاله Abstract


Title: Short-term results of trabeculectomy using adjunctive intracameral bevacizumab: A randomized controlled trial
Author(s): Ghasem Fakhraie, Hadi Ghadimi, Yadollah Eslami, Reza Zarei, Massood Mohammadi, Zakieh Vahedian, Mostafa Mafi, Sasan Moghimi
Presentation Type: Oral
Subject: Glaucoma
Others:
Presenting Author:
Name: Zakieh Vahedian
Affiliation :(optional) Glaucoma service, Farabi Eye Hospital, Tehran, Iran
E mail: vahedian.z@gmail.com
Phone:
Mobile: 09121947330
Purpose:

To investigate the outcome of trabeculectomy with or without adjunctive intracameral bevacizumab.

Methods:

In this double-blind, randomized clinical trial 71 patients with primary open-angle or pseudoexfoliation glaucoma were randomly assigned to receive either 1.25 mg intracameral bevacizumab (n=36) or balanced salt solution (n=35) at the end of trabeculectomy. Success was defined as intraocular pressure (IOP) between 6 and 21 mmHg at last postoperative visit with (qualified) or without (complete) glaucoma medications without additional glaucoma surgery.

Results:

Thirty-two patients in bevacizumab group and 33 in placebo group completed a mean follow-up of 10.7±2.1 and 10.5±2.5 months, respectively (P=0.731). The mean preoperative IOP was 28.25±5.64 mmHg and 29.11±4.65 mmHg in the bevacizumab and placebo groups, respectively (P=0.485). Last visit IOP was 14.5±3.7 mmHg in the bevacizumab group and 18.55±3.64 mmHg in the placebo group (P<0.001). At last visit, complete success was achieved in 26 cases (81.3%) of bevacizumab group and 16 cases (48.5%) of placebo group (P<0.006). Filtering bleb leak during the first postoperative month was seen in 11 (34%) and in 3 (9%) cases of bevacizumab and placebo groups, respectively (P=0.013).

Conclusion:

A single 1.25 mg dose of intracameral bevacizumab improves the success of trabeculectomy; however, it increases the risk of early bleb leakage.

Attachment:





Skip Navigation Links
        صفحه اصلی
        ساختار کنگره
        تاریخ های مهم
        مکان برگزاری
        ثبت نام
        ثبت نام شدگان
        اطلاعات هتل - رزرو
        ارسال مقالات
        برنامه کنگره
        نمایشگاه
        تماس با ما
        جستجوی سخنران
        برگزیدگان جشنواره فیلم
        برگزیدگان جشنواره عکس
 
Last News

  - بـیــست و چهارمین کنــگــره سـالیـانه انـجـمـن چـشـم پـزشـکی ایـــران